KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash & Equivalents: 2011-2025

Historic Cash & Equivalents for Sarepta Therapeutics (SRPT) over the last 15 years, with Sep 2025 value amounting to $613.1 million.

  • Sarepta Therapeutics' Cash & Equivalents rose 209.87% to $613.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $613.1 million, marking a year-over-year increase of 209.87%. This contributed to the annual value of $1.1 billion for FY2024, which is 19.60% down from last year.
  • Latest data reveals that Sarepta Therapeutics reported Cash & Equivalents of $613.1 million as of Q3 2025, which was down 8.96% from $673.4 million recorded in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' Cash & Equivalents peaked at $2.1 billion during Q4 2021, and registered a low of $197.9 million during Q3 2024.
  • Moreover, its 3-year median value for Cash & Equivalents was $613.1 million (2025), whereas its average is $695.3 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first slumped by 63.49% in 2024, then spiked by 209.87% in 2025.
  • Sarepta Therapeutics' Cash & Equivalents (Quarterly) stood at $2.1 billion in 2021, then plummeted by 54.31% to $966.8 million in 2022, then soared by 41.91% to $1.4 billion in 2023, then decreased by 19.60% to $1.1 billion in 2024, then surged by 209.87% to $613.1 million in 2025.
  • Its Cash & Equivalents stands at $613.1 million for Q3 2025, versus $673.4 million for Q2 2025 and $612.3 million for Q1 2025.